MX2023000589A - Terapia de combinacion para tratar el crecimiento celular anormal. - Google Patents

Terapia de combinacion para tratar el crecimiento celular anormal.

Info

Publication number
MX2023000589A
MX2023000589A MX2023000589A MX2023000589A MX2023000589A MX 2023000589 A MX2023000589 A MX 2023000589A MX 2023000589 A MX2023000589 A MX 2023000589A MX 2023000589 A MX2023000589 A MX 2023000589A MX 2023000589 A MX2023000589 A MX 2023000589A
Authority
MX
Mexico
Prior art keywords
cell growth
abnormal cell
treating abnormal
combination therapy
antibody
Prior art date
Application number
MX2023000589A
Other languages
English (en)
Inventor
Jonathan A Pachter
Silvia Coma
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of MX2023000589A publication Critical patent/MX2023000589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a métodos, composiciones, y las formas de dosis oral de un inhibidor dual de RAF/MEK en combinación con un anticuerpo anti-PD-1 o un anticuerpo anti-PD-L1 para tratar el crecimiento celular anormal (por ejemplo, cáncer).
MX2023000589A 2020-07-13 2021-07-13 Terapia de combinacion para tratar el crecimiento celular anormal. MX2023000589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063051320P 2020-07-13 2020-07-13
PCT/US2021/041439 WO2022015736A1 (en) 2020-07-13 2021-07-13 Combination therapy for treating abnormal cell growth

Publications (1)

Publication Number Publication Date
MX2023000589A true MX2023000589A (es) 2023-02-13

Family

ID=79554253

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000589A MX2023000589A (es) 2020-07-13 2021-07-13 Terapia de combinacion para tratar el crecimiento celular anormal.

Country Status (11)

Country Link
US (1) US20230330088A1 (es)
EP (1) EP4178573A4 (es)
JP (1) JP2023534009A (es)
KR (1) KR20230039684A (es)
CN (1) CN116056699A (es)
AU (1) AU2021307410A1 (es)
BR (1) BR112023000675A2 (es)
CA (1) CA3189383A1 (es)
IL (1) IL299789A (es)
MX (1) MX2023000589A (es)
WO (1) WO2022015736A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116120461B (zh) * 2022-04-29 2023-09-29 德琪(杭州)生物有限公司 新型抗药抗体以及其用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024067631A1 (zh) * 2022-09-30 2024-04-04 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190262A1 (es) * 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
WO2015179075A1 (en) * 2014-05-21 2015-11-26 The Board Of Regents Of The University Of Texas System Treatment for melanoma
WO2016011160A1 (en) * 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
CN108289892B (zh) * 2015-06-29 2021-11-23 维瑞斯特姆股份有限公司 治疗组合物、组合和使用方法
CN109663130B (zh) * 2017-10-13 2021-06-29 江苏恒瑞医药股份有限公司 Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer

Also Published As

Publication number Publication date
EP4178573A4 (en) 2024-08-07
US20230330088A1 (en) 2023-10-19
WO2022015736A9 (en) 2022-05-05
BR112023000675A2 (pt) 2023-04-25
EP4178573A1 (en) 2023-05-17
JP2023534009A (ja) 2023-08-07
IL299789A (en) 2023-03-01
WO2022015736A1 (en) 2022-01-20
CN116056699A (zh) 2023-05-02
AU2021307410A1 (en) 2023-02-09
CA3189383A1 (en) 2022-01-20
KR20230039684A (ko) 2023-03-21

Similar Documents

Publication Publication Date Title
MX2024001248A (es) Terapia de combinacion para tratar el crecimiento celular anormal.
MX2023000589A (es) Terapia de combinacion para tratar el crecimiento celular anormal.
MX2022009347A (es) Terapia de combinacion para el tratamiento del crecimiento celular anormal.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2020009862A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2021012407A (es) Terapia de combinacion con un anticuerpo anti bcma y un inhibidor de gamma secretasa.
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
MX2023009223A (es) Terapia combinada para el tratamiento del crecimiento celular anormal.
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
WO2023108110A3 (en) Combination therapy for treating abnormal cell growth
MX2019002728A (es) Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.
MX2022001004A (es) Inhibidores de enzimas.
MX2024008551A (es) Terapias de combinacion.
MX2021013815A (es) Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
BR112021014699A2 (pt) Métodos de tratamento de mieloma múltiplo
EA202193111A1 (ru) Композиции и способы для лечения рака
MX2022010860A (es) Terapia combinada que comprende inhibidores de axl/mer y pd-1/pd-l1.
MX2020002301A (es) Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.